Condition: Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) · Sponsor: Genfleet Therapeutics (Shanghai) Inc.
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma
This description comes directly from the study's public registry record.
Jin Li · +86 21 6882 1388 · jli@genfleet.com
Yuting Peng · +8613730813620 · ytpeng@genfleet.com
Always discuss trial participation with your own doctor first.
| Sun Yat-sen University Cancer Center | Guanzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05934513